🔍

Zensar Technologies Limited (ZENSARTECH)

📊 NSE: ZENSARTECH 🏢 Computers - Software - Medium / Small 📅 Last Updated: 12/14/2025 15:23

📢 Recent Corporate Announcements

ICRA Reaffirms Zensar's Credit Ratings at [ICRA]AA+ (Stable) / [ICRA]A1+ for Rs 191 Cr Bank Limits

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Aug 2026, 04:52 PM

ICRA Limited has reaffirmed Zensar Technologies' credit ratings for long-term and short-term bank facilities at [ICRA]AA+ (Stable) and [ICRA]A1+ respectively. The ratings cover fund-based and non-fund-based limits totaling Rs 191.00 crore across multiple lenders, led by Citibank (Rs 72.00 crore) and HSBC (Rs 40.00 crore). The reaffirmation underscores Zensar's strong financial stability, supported by a virtually debt-free balance sheet with total debt of just Rs 37 crore against a net worth of Rs 3,521 crore (D/E ratio of 0.01).

ICRA reaffirmed long-term rating at [ICRA]AA+ with a Stable outlook
Short-term instrument rating reaffirmed at [ICRA]A1+
Total bank limits rated under the facility stand at Rs 191.00 crore
Allocations include Citibank (Rs 72.00 crore), HSBC (Rs 40.00 crore), and ICICI Bank (Rs 25.00 crore)

💡 No action needed on this routine surveillance update; continue tracking revenue growth in the core US geography and execution on AI-led pipeline.

Zensar Technologies Allots 25,691 Equity Shares Under ESOP Scheme

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Aug 2026, 07:24 PM

Zensar Technologies has approved the allotment of 25,691 fully paid-up equity shares of face value Rs. 2 each following the exercise of stock options by employees. Consequently, the company's paid-up share capital increased to Rs. 45.52 crore, comprising 227,580,713 equity shares. The equity dilution from this allotment is negligible at approximately 0.011% of the total share base and has no material financial impact.

Allotment of 25,691 equity shares of Rs. 2 each approved on August 24, 2026
Issued and subscribed share capital increased to Rs. 455,161,426
Total post-allotment equity share count stands at 227,580,713 shares
Dilution represents ~0.011% of the total paid-up equity capital

💡 Track ongoing quarterly operational execution and client traction in core markets, as ESOP allotments are routine corporate actions.

Zensar to Merge US Subsidiaries M3BI and Bridgeview; Effective September 1, 2026

🟡 NEUTRAL ⭐ 4/10

M&A 📅 14 Aug 2026, 01:17 PM

Zensar Technologies is consolidating its US-based operations by merging two 100% step-down subsidiaries, M3BI LLC and Bridgeview Life Sciences LLC, into its primary US entity, Zensar Technologies Inc. The merger of M3BI LLC is scheduled to become effective on September 1, 2026, following the completion of regulatory filings on August 13, 2026. This internal restructuring follows the earlier completion of the Bridgeview merger filings in July 2026. The move aims to streamline the corporate structure in the US, which is the company's largest market, accounting for 67.7% of total revenue.

Merger of M3BI LLC with Zensar Technologies Inc. to be effective from September 1, 2026
All requisite filings for M3BI LLC merger were completed on August 13, 2026
Consolidation involves two 100% step-down subsidiaries in the US market
US operations contribute 67.7% of the company's total TTM revenue of ₹4,336 Cr
Intimation of filing completion received at 1:43 a.m. IST on August 14, 2026

💡 Investors should monitor upcoming quarterly reports for any management commentary regarding administrative cost savings or operational synergies arising from this US entity consolidation.

Zensar Technologies to Participate in Investor Conferences on August 13-14, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Aug 2026, 01:46 PM

Zensar Technologies has scheduled participation in two institutional investor conferences: the Equirus Annual India Conference on August 13 and the Emkay Confluence on August 14, 2026. These meetings are part of routine investor relations activities and will not involve the disclosure of unpublished price-sensitive information. The company, with a market cap of Rs 11,470 Cr and TTM revenue of Rs 4,195 Cr, continues to focus on its AI-led innovation strategy despite a 35.8% stock price decline over the last 12 months.

Scheduled participation in Equirus Annual India Conference 2026 on August 13, 2026, from 1:00 p.m. onwards.
Scheduled participation in Emkay Confluence 2026 on August 14, 2026, from 10:00 a.m. onwards.
Company reported TTM revenue of Rs 4,195 Cr and a PAT of Rs 727 Cr for FY26.
Current workforce stands at 10,620 associates as of June 30, 2025.
Promoter holding remains stable at 49.01% as of March 2026.

💡 Investors should monitor for any post-event investor presentations or transcripts that may provide qualitative updates on the ZenseAI platform adoption and the M&A pipeline.

Zensar Technologies to Participate in Two Investor Conferences on August 13-14, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Aug 2026, 01:28 PM

Zensar Technologies has announced its participation in two upcoming institutional investor conferences. The company will attend the Equirus Annual India Conference on August 13, 2026, and the Emkay Confluence on August 14, 2026. Both events are scheduled as in-person group meetings. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in 2 distinct investor conferences scheduled for mid-August 2026.
Equirus Annual India Conference 2026 meeting starts at 1:00 p.m. on August 13, 2026.
Emkay Confluence 2026 meeting starts at 10:00 a.m. on August 14, 2026.
Meetings will be conducted in an in-person group format.
Company maintains a TTM revenue base of ₹4,195 Cr and a workforce of 10,620 associates.

💡 Investors should look for any subsequent investor presentations or transcripts filed with the exchanges, which may provide qualitative commentary on the company's AI-led growth strategy and US market outlook.

74 ESG Score: CRISIL Assigns 'Leadership' Category Rating to Zensar Technologies

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 08 Aug 2026, 02:18 PM

CRISIL ESG Ratings & Analytics has independently assigned Zensar Technologies an overall ESG score of 74 for FY2026, placing it in the 'Leadership' category. The rating was prepared based on publicly available data without formal engagement by the company. This score reflects strong performance across environmental, social, and governance parameters. While it does not impact debt costs like a credit rating, it enhances the company's appeal to ESG-focused institutional investors.

Overall ESG Score of 74 assigned by CRISIL for the fiscal year 2026
Company classified under the 'Leadership' category for its ESG performance
Rating received on August 7, 2026, based on independent analysis of public domain data
Zensar maintains a low Debt-to-Equity ratio of 0.01, supporting its governance profile

💡 Investors should monitor if this high ESG score leads to increased weightage in ESG-themed mutual funds or institutional portfolios. It serves as a qualitative benchmark for the company's non-financial risk management.

Zensar Technologies Releases Q1FY27 Earnings Call Transcript

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Aug 2026, 08:57 PM

Zensar Technologies has made the transcript of its Q1FY27 earnings call, held on July 30, 2026, available to the public. The call discussed the financial results for the quarter ended June 30, 2026. As of the latest TTM data, the company maintains a revenue of ₹4,195 Cr with an operating margin of 18.0%. This filing is a standard procedural update following the quarterly results announcement.

Earnings call conducted on July 30, 2026, at 08:30 a.m. IST
Transcript covers financial performance for the quarter ended June 30, 2026
Company reported TTM Revenue of ₹4,195 Cr and TTM PAT of ₹727 Cr
US market remains a key focus area, historically contributing 67.7% of revenue

💡 Investors should review the transcript on the company's website for management commentary on the AI-led innovation pipeline and the progress of the ZenseAI platform.

Zensar Shareholders Approve ₹15 Total Dividend and ₹750 Cr Related Party Transaction

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 31 Jul 2026, 05:44 PM

Zensar Technologies Limited held its 63rd Annual General Meeting on July 30, 2026, where shareholders approved all four proposed resolutions. A final dividend of ₹12.60 per share was ratified, bringing the total FY26 dividend to ₹15.00 per share. A significant resolution was passed for material related party transactions with its South African subsidiary for FY27, valued at ₹750 Cr, which represents approximately 17.9% of FY26 revenue. The re-appointment of Director H. V. Goenka was also confirmed with 96.5% majority support.

Total dividend of ₹15.00 per share approved for FY26, including a final dividend of ₹12.60.
Shareholders approved material related party transactions with Zensar (South Africa) Pty Ltd worth ₹750 Cr for FY27.
The ₹750 Cr RPT value accounts for 17.88% of the company's TTM revenue of ₹4,195 Cr.
Resolution for re-appointment of H. V. Goenka passed with 96.52% votes in favour, despite 3.47% institutional/public opposition.
Overall voting participation reached 79.37% for the dividend and director appointment resolutions.

💡 Investors should monitor the performance of the South African subsidiary given the high volume of inter-company transactions approved, and track the dividend payout timeline.

Zensar to Merge US Subsidiaries; Bridgeview Merger Effective August 1, 2026

🟡 NEUTRAL ⭐ 4/10

M&A 📅 31 Jul 2026, 02:49 PM

Zensar Technologies is consolidating its US-based operations by merging two 100% step-down subsidiaries, Bridgeview Life Sciences LLC and M3BI LLC, into its material wholly owned subsidiary, Zensar Technologies Inc. The merger of Bridgeview Life Sciences is finalized with an effective date of August 1, 2026. Filings for the merger of M3BI LLC are currently in progress. This internal restructuring aims to streamline the corporate structure in the US, which is Zensar's largest market, contributing 67.7% of its TTM revenue of ₹4,195 Cr.

Merger of Bridgeview Life Sciences LLC into Zensar Technologies Inc. becomes effective August 1, 2026
Requisite filings for the Bridgeview merger were completed on July 30, 2026
M3BI LLC merger filings are currently in progress as of July 31, 2026
The consolidation involves 100% step-down subsidiaries within the US market
US operations account for 67.7% of the company's total revenue profile

💡 Investors should monitor the completion of the M3BI LLC merger and check future quarterly results for any reported improvements in operational margins due to reduced administrative overhead in the US.

Zensar Technologies Approves Rs 750 Cr Related Party Transaction at 63rd AGM

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 30 Jul 2026, 05:22 PM

Zensar Technologies concluded its 63rd Annual General Meeting on July 30, 2026, covering four key resolutions. Shareholders voted on the adoption of FY26 financial statements and the declaration of a final dividend. A significant resolution included the approval of material related party transactions with its South African subsidiary for an aggregate value of Rs 750 crore for FY27. This transaction value represents approximately 17.9% of the company's TTM revenue of Rs 4,195 crore.

Approved material related party transactions with Zensar (South Africa) Pty Ltd for Rs 750 crore in FY27
The Rs 750 crore transaction represents ~17.9% of the company's TTM revenue of Rs 4,195 crore
Shareholders voted on the adoption of Audited Standalone and Consolidated Financial Statements for FY26
Confirmed the re-appointment of Mr. H. V. Goenka as a Director
The meeting was attended by 42 members through video conferencing

💡 Investors should monitor the formal voting results to be released within 2 working days to confirm the passage of all resolutions, particularly the large related party transaction.

July 30, 2026: Zensar Technologies Releases Q1FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Jul 2026, 11:21 AM

Zensar Technologies has made the audio recording of its Q1FY27 earnings call available to the public following the results for the quarter ended June 30, 2026. The call, held on July 30, 2026, provides management's perspective on the company's TTM revenue of ‑4,195 Cr and its 18.0% operating margin. Investors can access the recording via the company's website to understand the progress of the ZenseAI platform and the 30% AI-led order pipeline. This is a routine regulatory disclosure to ensure transparency for all stakeholders.

Audio recording of the earnings call held on July 30, 2026, at 08:30 AM IST is now available.
The discussion covers financial results for the quarter ended June 30, 2026.
Company maintains a TTM revenue of ‑4,195 Cr and a market capitalization of ‑12,230 Cr.
Management commentary typically addresses the 67.7% revenue concentration in the US market.

💡 Review the recording for management's outlook on discretionary spending in the US and the execution timeline for the ZenseAI agentic AI platform.

Zensar to Merge US Subsidiaries with $51.54M Combined Turnover into Zensar Technologies Inc.

🟡 NEUTRAL ⭐ 5/10

M&A 📅 29 Jul 2026, 08:28 PM

Zensar Technologies has received in-principle approval to merge two US-based step-down subsidiaries, M3BI LLC and Bridgeview Life Sciences LLC, into its primary US entity, Zensar Technologies Inc. The merging entities had a combined turnover of $51.54 million in FY26, which represents approximately 10.2% of the company's consolidated TTM revenue. This internal restructuring aims to achieve operational synergies and unified control in the US market, which accounts for 67.7% of Zensar's total revenue. There will be no change in the shareholding pattern of the listed Indian entity or any cash consideration involved.

M3BI LLC reported a standalone turnover of $46.8 million for the year ended March 31, 2026.
Bridgeview Life Sciences LLC reported a standalone turnover of $4.74 million for the same period.
Zensar Technologies Inc., the surviving entity, reported a turnover of $326.96 million and a net worth of $74.66 million.
The merger involves no cash consideration as it is an internal consolidation of step-down subsidiaries.
The US market remains the primary geography, contributing 67.7% of Zensar's total revenue.

💡 Investors should monitor the completion timeline of the merger and look for management commentary on expected cost savings or operational improvements in the US segment during the next quarterly update.

Zensar Q1FY27: 1.1% CC Revenue Growth; PAT Margin Contracts 220 bps to 12.2%

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 29 Jul 2026, 08:25 PM

Zensar reported a modest 1.1% sequential constant currency revenue growth for Q1FY27, reaching $159.5M. While the Banking and Financial Services (BFS) vertical grew strongly at 8.3% QoQ, overall profitability was pressured, with PAT margins dropping 220 bps to 12.2% due to transition costs for a large deal. The company maintains a strong cash position of $317.5M, which represents over 25% of its current market capitalization. Performance was mixed across sectors, with Telecommunication, Media and Technology (TMT) seeing a sharp 28% YoY decline.

Revenue of $159.5M reflects a 1.1% sequential growth in constant currency terms.
PAT margin contracted by 220 bps QoQ to 12.2% of revenue, while EBITDA margin fell 150 bps to 14.6%.
Banking and Financial Services (BFS) grew 8.3% QoQ, now contributing 48.8% of total revenue.
Net cash and cash equivalents stood at $317.5M, a 0.6% YoY increase.
Telecommunication, Media and Technology (TMT) vertical revenue declined 28.0% YoY in constant currency.

💡 Monitor the stabilization of margins as the 'large deal' transitions from early-stage execution to steady-state. Watch for recovery in the TMT and Healthcare verticals, which are currently dragging overall performance despite BFS strength.

Zensar Q1 FY27: Revenue up 1.1% CC QoQ; PAT Margin Contracts 220 bps to 12.2%

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 29 Jul 2026, 08:23 PM

Zensar Technologies reported a modest 1.1% sequential constant currency (CC) revenue growth for Q1 FY27, reaching $159.5 million. While the Banking and Financial Services (BFS) vertical showed strong momentum with 8.3% QoQ growth, the overall performance was weighed down by a sharp 9.1% QoQ decline in the TMT segment. Profitability took a hit as PAT margins fell 220 bps QoQ to 12.2%, primarily due to transition costs for a large deal. The company maintains a robust balance sheet with $317.5 million in net cash.

Revenue reached $159.5M, representing a 1.1% sequential growth in constant currency terms.
PAT margin stood at 12.2%, reflecting a 220 bps sequential contraction due to large deal transition costs.
Banking and Financial Services (BFS) grew 8.3% QoQ in CC, now contributing 48.8% of total revenue.
Telecommunication, Media and Technology (TMT) vertical revenue slumped 28.0% YoY in constant currency.
Net cash and cash equivalents increased to $317.5M, up 0.6% year-on-year.

💡 Investors should monitor the margin trajectory in upcoming quarters to see if the 'large deal' transition costs subside as execution reaches steady-state. Additionally, watch for signs of stabilization in the TMT and Healthcare verticals, which currently offset the strong growth in BFS.

Zensar Q1 Standalone Revenue Grows 22.6% YoY to ₹763.2 Cr; Net Profit at ₹183.5 Cr

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 29 Jul 2026, 08:13 PM

Zensar Technologies reported a standalone revenue of ₹763.2 cr for Q1 FY27, a significant 22.6% increase compared to ₹622.2 cr in Q1 FY26. However, standalone net profit of ₹183.5 cr showed a sequential decline of 7.9% from the preceding March quarter (₹199.2 cr), despite a 6.8% YoY growth. The Cloud Infrastructure and Security segment performed well, contributing ₹265.3 cr to consolidated revenue. The company's ESOP trust was active, acquiring 781,257 shares from the open market during the quarter.

Standalone revenue for Q1 FY27 reached ₹763.2 cr, up 22.6% from ₹622.2 cr in Q1 FY26.
Standalone net profit stood at ₹183.5 cr, representing a 6.8% YoY growth but a 7.9% QoQ decline.
Cloud Infrastructure and Security segment revenue grew to ₹265.3 cr from ₹207.3 cr in the year-ago period.
The ESOP Trust acquired 781,257 equity shares from the open market, treated as treasury shares.
Basic EPS for the quarter was ₹8.09, up from ₹7.57 in Q1 FY26 but down from ₹8.79 in Q4 FY26.

💡 Investors should monitor the sequential margin compression as profits fell despite revenue growth. Key focus areas include the execution of the AI-led pipeline (ZenseAI) and growth in the Healthcare vertical to offset US geographic concentration.

View All ZENSARTECH Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Digital and Application Services grew 5.6% YoY to INR 4,226.9 Cr in FY2025, while Digital Foundation Services grew 17.1% YoY to INR 1,053.7 Cr. Total revenue reached INR 5,280.6 Cr, a 7.7% increase from INR 4,901.9 Cr in FY2024.

Geographic Revenue Split

The United States contributed 67.7% (INR 3,576.2 Cr), Europe 20.9% (INR 1,103.6 Cr), and the Rest of the World/Africa 11.4% (INR 600.8 Cr) in FY2025.

Profitability Margins

Operating Profit Margin (OPM) moderated to 15.5% in FY2025 from 17.8% in FY2024, a decline of 230 bps due to higher sales, marketing, and travel expenses. PAT margin was 12.3% in FY2025 compared to 13.6% in FY2024.

EBITDA Margin

EBITDA margin stood at 15.5% in FY2025. Absolute EBITDA was INR 816.7 Cr, representing a 6.3% YoY decline from INR 871.7 Cr in FY2024 due to increased investments in new technologies.

Capital Expenditure

Not disclosed in absolute INR Cr for future periods, but the company maintains a debt-free status (excluding lease liabilities) and held cash and investments of $293.0 million (approx. INR 2,450 Cr) as of Q2 FY2026 to fund potential inorganic growth.

Credit Rating & Borrowing

Reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ in September 2025. Borrowing costs are minimal as the company is debt-free (excluding lease liabilities) with an interest coverage ratio of 41.7x in FY2024.

⚙️ Operational Drivers

Raw Materials

As an IT services firm, the primary 'raw material' is human capital. Employee benefit expenses are the largest cost component, though specific percentage of total cost was not disclosed.

Import Sources

Not applicable for IT services; talent is sourced globally with 10,620 associates across 16 countries.

Capacity Expansion

Current workforce stands at 10,620 associates as of June 30, 2025. Expansion is driven by headcount growth and utilization, which improved in FY2025.

Raw Material Costs

Wage cost inflation significantly impacted margins in FY2023, reducing OPM to 11.4%. Stabilization of wage costs in FY2024 helped margins recover to 17.8%.

Manufacturing Efficiency

Employee utilization levels improved in FY2025 and Q1 FY2026, supporting the business profile despite industry-wide demand softening.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved through AI-led innovation, with 30% of the active order pipeline already driven by AI. The company launched ZenseAI, an agentic AI platform, to drive enterprise intelligence. Additionally, Zensar is scouting for inorganic growth opportunities using its $293 million cash reserve and focusing on the BFSI vertical, which supported a TCV of $774 million for FY2026.

Products & Services

IT consulting, application development and maintenance, package implementation, BPO operations, Digital Foundation Services, and the ZenseAI agentic AI platform.

Brand Portfolio

Zensar, ZenseAI.

New Products/Services

ZenseAI agentic AI platform launched in 2025 to drive enterprise-level innovation.

Market Expansion

Focusing on deepening penetration in the healthcare and life sciences vertical and expanding presence in the US, UK, Europe, and South Africa.

Market Share & Ranking

Moderate scale compared to large domestic IT players, which restricts pricing flexibility and margins.

🌍 External Factors

Industry Trends

The IT industry is shifting toward AI-integrated services and cloud infrastructure. Zensar is positioning itself with a 30% AI-led pipeline and the ZenseAI platform to capture this shift.

Competitive Landscape

Intense competition from prominent global and domestic IT players leads to pricing pressure and high competition for skilled talent.

Competitive Moat

Moat is based on an established business position and backing from the RPG Group. However, the lack of large-scale operations makes the moat less sustainable against Tier-1 competitors who have better pricing power.

Macro Economic Sensitivity

Highly sensitive to US and European GDP growth and corporate discretionary spending; 88.6% of revenue is derived from these two regions.

Consumer Behavior

Clients are increasingly demanding AI-led intelligence and cost-effective digital foundation services, reflected in the 17.1% growth of Zensar's Digital Foundation segment.

Geopolitical Risks

Exposed to macroeconomic uncertainties and adverse regulatory/legislative changes, including potential US tariffs and changes in visa policies.

⚖️ Regulatory & Governance

Industry Regulations

Subject to data privacy regulations and labor laws in 16 countries. Changes in US work visa policies or data protection laws could increase compliance costs.

Environmental Compliance

Direct exposure to environmental risks is not material given the service-oriented nature of the business.

Taxation Policy Impact

Not disclosed; however, fiscal policies in the US and Europe regarding IT outsourcing are key monitors.

Legal Contingencies

Faces risks of data breaches and cyberattacks which could result in substantive liabilities, fines, or penalties. No specific pending court case values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Softening demand in the US market and potential decline in discretionary IT spending could impact revenue growth by more than 5-10% if macro conditions worsen.